Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ContraVir Hopes To Establish Backbone For Hepatitis B Combo Therapy

Related Content

Busy Days For Hep B Drug Development

Feb 01 2016

J&J Looks To Get Ahead In Hep B With Combination Strategy

Feb 01 2016

Bristol’s Virology Focus Turning To Hepatitis B? An Interview With Doug Manion

Nov 11 2013

ContraVir Strikes Deal With Rival Early Stage Hep B Drug Developer

Jun 01 2016

ContraVir appoints new CMO

Jan 15 2015

Related Companies

Gilead Sciences, Inc.

Hepion Pharmaceuticals, Inc.

Synergy Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Merck & Co., Inc.

Vertex Pharmaceuticals Incorporated

Chimerix, Inc.

Hepion Pharmaceuticals, Inc.

Johnson & Johnson

Dynavax Technologies Corporation

Chia Tai Tianqing Pharmaceutical Group Co., Ltd

Alios BioPharma

Arcturus Therapeutics Ltd.

Additional Topics

Commercial Research & Development Strategy Infectious Diseases BioPharmaceutical

More from Business

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window